JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in CD𝟖⁺ T Cells in Renal Cell Carcinoma Patients

Figure 3

Cytotoxicity assay of RCC1-specific CTL at day 35 of the MLTC. Specific lysis was determined in a 4-hour ⁵¹Cr-release assay using CD8⁺ T cells collected from d 35 MLTC established from patient RCC1 (a) or HLA-matched normal donors (the patient’s sibling (b) and an unrelated individual (c). T cells were used at varying effector-to-target (E:T) cell ratios against target cells including RCC1, K562, and RCC1-LCL. Data are presented as percentages of specific lysis ± SD.

(a)

(b)

(c)